Posted by Michael Wonder on 23 Sep 2016
FDA approves expanded indications for Ilaris for three rare diseases
23 September 2016 - The U.S. FDA today approved three new indications for Ilaris (canakinumab).
The new indications are for rare and serious auto-inflammatory diseases in adult and pediatric patients:
- Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS)
- Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD)
- Familial Mediterranean Fever (FMF)
All three syndromes are hereditary diseases that are characterized by periodic attacks of fever and inflammation, as well as severe muscle pain. There are no previously approved therapies for TRAPS or HIDS/MKD.
